IPOs ref

00069469-0

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/00 — A1

(11) International Publication Number: **WO 00/69469**

(43) International Publication Date: 23 November 2000 (23.11.00)

(21) International Application Number: PCT/US99/10596

(22) International Filing Date: 13 May 1999 (13.05.99)

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 08/954,509 (CIP)
Filed on 5 November 1997 (05.11.97)

(71) Applicant *(for all designated States except US)*: NEXMED HOLDINGS, INC. [US/US]; 350 Corporate Boulevard, Robinsville, NJ 08691 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: YEAGER, James, L. [US/US]; 820 Warwick Road, Deerfield, IL 60015 (US). BUYUKTIMKIN, Nadir [TR/US]; 2313 Willow Creek, Lawrence, KS 66049 (US). BUYUKTIMKIN, Servet [TR/US]; 2313 Willow Creek, Lawrence, KS 66049 (US).

(74) Agent: ZIMMERMAN, Roger, P.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E_1 DELIVERY

(57) Abstract

A composition of a semi–solid consistency is provided for use in the manufacture of a topical medicament for the transdermal application of prostaglandin E_1. The composition comprises prostaglandin E_1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl–2–(N,N–disubstituted amino)–alkanoate ester, an(N,N–disubstituted amino)–alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C_1 to C_8 alcohol, an aliphatic C_8 to C_{30} ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4. The composition is useful for the manufacture of medicaments for the treatment of erectile dysfunction, female sexual dysfunction and peripheral vascular disease.